To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

A mini-review and impleme… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

A mini-review and implementation model for using ataluren to treat nonsense mutation Duchenne muscular dystrophy

Journal article
Authors E. Landfeldt
T. Sejersen
Mar Tulinius
Published in Acta Paediatrica
Volume 108
Issue 2
Pages 224-230
ISSN 0803-5253
Publication year 2019
Published at Institute of Clinical Sciences, Department of Pediatrics
Pages 224-230
Language en
Links dx.doi.org/10.1111/apa.14568
Keywords Ataluren, Duchenne muscular dystrophy, Implementation model, Sweden, Treatment guidelines, natural-history, disorders, diagnosis, survival, Pediatrics, donald cm, 1995, american journal of physical medicine & rehabilitation, v74, ps70
Subject categories Pediatrics

Abstract

Aim Ataluren has been approved for treating nonsense mutation Duchenne muscular dystrophy (nmDMD), and there are currently discussions concerning drug access and applications beyond the development programme. This study provides an overview of nmDMD and ataluren, stipulates clinical rules for treatment initiation and discontinuation and proposes a model for the implementation of orphan drugs in clinical practice in Sweden. Methods This was a targeted mini-review of the literature from 1995 to 2018, which included cohort studies, guidelines, randomised clinical trials, clinical commentaries and reviews. The review covered the pathophysiology, epidemiology and burden of nmDMD and the clinical programme for ataluren. Results Based on the current evidence, and our experiences, we recommend that patients with nmDMD should be given ataluren as soon as possible after diagnosis and this treatment should continue until they reach a forced vital capacity of <30%, and, or, a score of at least six on the Brooke upper extremity scale. We propose an implementation model that comprises a coordinating specialist physician and a national expert committee responsible for providing clinical intelligence to ensure appropriate use. Conclusion Our clinical recommendations and proposed implementation model will inform the optimum medical management of nmDMD in Sweden and help ensure timely, equal access to ataluren and similar orphan drugs.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?

Denna text är utskriven från följande webbsida:
http://www.gu.se/english/research/publication/?publicationId=277486
Utskriftsdatum: 2020-08-10